5. Have unresectable Stage III through stage IV metastatic melanoma that have not achieved complete or partial response after 6 months of therapy or that have progressed on PD-L1 or PD-1 directed therapy including combinations and have evidence of PTEN loss in their tumors by Immunohistochemistry (IHC) or molecular analysis.